[{"id":"a54c5bf1-77a7-4e44-bb57-e245104dfd72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780517","created_at":"2021-01-18T18:41:54.388Z","updated_at":"2024-07-02T16:35:31.196Z","phase":"Phase 1","brief_title":"Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors","source_id_and_acronym":"NCT03780517","lead_sponsor":"Boston Pharmaceuticals","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeteletinib (BOS-172738)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2023-10-30"}]